We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+10.32%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$871M
AUM Growth
+$146M
Cap. Flow
+$107M
Cap. Flow %
12.24%
Top 10 Hldgs %
47.29%
Holding
141
New
32
Increased
44
Reduced
18
Closed
28

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$43.2M
2
BMY icon
Bristol-Myers Squibb
BMY
+$32M
3
VTRS icon
Viatris
VTRS
+$17.7M
4
ARGX icon
argenx
ARGX
+$12.1M
5
ACGN
Aceragen Inc
ACGN
+$11.5M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$21.4M
2
AMGN icon
Amgen
AMGN
+$18.5M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$15.6M
4
BIIB icon
Biogen
BIIB
+$14.5M
5
PFE icon
Pfizer
PFE
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 77.29%
2 Miscellaneous 12.29%
3 Technology 4.8%
4 Industrials 2.36%
5 Financials 1.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRQR icon
26
ProQR Therapeutics
PRQR
$267M
$7.72M 0.89%
398,749
-95,000
-19% -$1.01M
SRRK icon
27
Scholar Rock
SRRK
$5.97B
$7.64M 0.88%
296,856
+12,859
+5% +$236K
RETA
28
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$7.58M 0.87%
92,719
-43,325
-32% -$3.05M
VRNT
29
DELISTED
Verint Systems
VRNT
$7.52M 0.86%
+294,697
New +$7.16M
CLSD
30
DELISTED
Clearside Biomedical
CLSD
$7.1M 0.82%
76,979
+5,731
+8% +$681K
ASND icon
31
Ascendis Pharma A/S
ASND
$15.7B
$6.57M 0.75%
92,673
+14,625
+19% +$1.01M
QURE icon
32
uniQure
QURE
$3.06B
$6.47M 0.74%
177,849
+25,359
+17% +$943K
MLNT
33
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
$6.39M 0.73%
323,373
+126,475
+64% +$3.2M
SYRE icon
34
Spyre Therapeutics
SYRE
$8.17B
$6.25M 0.72%
26,124
+5,759
+28% +$1.35M
TVRD
35
Tvardi Therapeutics
TVRD
$21.6M
$6.13M 0.7%
+7,109
New +$5.13M
V icon
36
Visa
V
$691B
$6.06M 0.7%
40,401
– –
ARRY
37
DELISTED
Array Biopharma Inc
ARRY
$6M 0.69%
395,000
+55,196
+16% +$846K
BHVN
38
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$5.84M 0.67%
155,515
+18,127
+13% +$667K
SBBP
39
DELISTED
Strongbridge Biopharma plc.
SBBP
$5.72M 0.66%
1,179,010
+505,014
+75% +$2.58M
SEDG icon
40
SolarEdge
SEDG
$2.21B
$5.68M 0.65%
150,817
+101,869
+208% +$4.91M
QTTB icon
41
Q32 Bio
QTTB
$323M
$5.6M 0.64%
13,617
+5,737
+73% +$1.95M
WAB icon
42
Wabtec
WAB
$47.1B
$5.57M 0.64%
53,114
+6,550
+14% +$706K
MRTX
43
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$5.32M 0.61%
112,908
+98,573
+688% +$5.49M
IFF icon
44
International Flavors & Fragrances
IFF
$21.7B
$5.07M 0.58%
+36,450
New +$4.79M
MA icon
45
Mastercard
MA
$496B
$5.07M 0.58%
22,760
– –
PVLA
46
Palvella Therapeutics
PVLA
$2.22B
$5.07M 0.58%
11,309
+776
+7% +$337K
LRMR icon
47
Larimar Therapeutics
LRMR
$395M
$5.03M 0.58%
35,833
-4,167
-10% -$506K
XENE icon
48
Xenon Pharmaceuticals
XENE
$5.55B
$5.01M 0.58%
379,484
-59,550
-14% -$690K
KDMN
49
DELISTED
Kadmon Holdings, Inc.
KDMN
$4.98M 0.57%
1,490,000
-62,846
-4% -$223K
CSCO icon
50
Cisco
CSCO
$435B
$4.87M 0.56%
100,000
– –
1
2
3 4 5

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q3 2018 Portfolio in Review

As of Q3 2018, Sphera Funds Management held 141 positions worth $871M, up 20% from $725M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Sphera Funds Management deployed $107M of net new capital in Q3 2018, opening 32 new positions and adding to 44 existing holdings. Its largest new stake was Johnson & Johnson: 325,000 shares worth $44.9M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 74% a quarter earlier, followed by Miscellaneous and Technology.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $15.6M trimmed.

  • Sphera Funds Management's largest Q3 2018 buy was Johnson & Johnson: 325,000 shares worth $44.9M.
  • Sphera Funds Management added most to Viatris in Q3 2018, an estimated $17.7M increase.
  • Sphera Funds Management's biggest Q3 2018 reduction was Alnylam Pharmaceuticals, cutting an estimated $15.6M.
  • Sphera Funds Management fully exited Shire pic in Q3 2018, selling an estimated $21.4M.
  • Sphera Funds Management's ten largest holdings make up 47% of its $871M portfolio in Q3 2018.
  • Sphera Funds Management opened 32 new positions and closed 28 in Q3 2018.
  • Sphera Funds Management's portfolio value rose 20% quarter-over-quarter to $871M.

Based on Sphera Funds Management's 13F filing for Q3 2018, filed 14 Nov 2018.